Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC versus LEVOBUNOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC versus LEVOBUNOLOL HYDROCHLORIDE.
BREVIBLOC vs LEVOBUNOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective) that reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
IV loading dose: 500 mcg/kg over 1 minute, followed by continuous infusion starting at 50 mcg/kg/min, titrated by 50 mcg/kg/min every 5 minutes up to 200 mcg/kg/min as needed.
One drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. May increase to 0.5% twice daily if response inadequate.
None Documented
None Documented
9 minutes (terminal elimination half-life in adults); due to rapid esterase metabolism, context: requires continuous infusion for sustained effect; prolonged to 20-30 minutes in hepatic impairment.
Parent drug: 3-7 hours (mean 5 hours); active metabolite dihydrolevobunolol: 7-8 hours; prolonged in hepatic impairment, clinical context suggests b.i.d. dosing maintains therapeutic effect.
Rapid hydrolysis by red blood cell esterases to ASL-8123 (acid metabolite) and methanol; ~1% excreted unchanged in urine; renal elimination of metabolite accounts for >95% of dose; no significant biliary/fecal excretion.
Renal: 15-20% unchanged; hepatic metabolism to dihydrolevobunolol (active, t1/2 7-8 hours) and other inactive metabolites; total renal excretion of drug and metabolites ~90%; fecal excretion minimal (<5%).
Category C
Category C
Beta-Adrenergic Blocker
Beta-Adrenergic Blocker